These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1392620)

  • 1. Human müllerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects.
    Ragin RC; Donahoe PK; Kenneally MK; Ahmad MF; MacLaughlin DT
    Protein Expr Purif; 1992 Jun; 3(3):236-45. PubMed ID: 1392620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain.
    MacLaughlin DT; Hudson PL; Graciano AL; Kenneally MK; Ragin RC; Manganaro TF; Donahoe PK
    Endocrinology; 1992 Jul; 131(1):291-6. PubMed ID: 1612008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity.
    Lorenzo HK; Teixeira J; Pahlavan N; Laurich VM; Donahoe PK; MacLaughlin DT
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Jan; 766(1):89-98. PubMed ID: 11820299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
    Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
    Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo.
    Chin TW; Parry RL; Donahoe PK
    Cancer Res; 1991 Apr; 51(8):2101-6. PubMed ID: 2009529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Müllerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes.
    Catlin EA; Uitvlugt ND; Donahoe PK; Powell DM; Hayashi M; MacLaughlin DT
    Metabolism; 1991 Nov; 40(11):1178-84. PubMed ID: 1943746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells.
    Kim JH; Seibel MM; MacLaughlin DT; Donahoe PK; Ransil BJ; Hametz PA; Richards CJ
    J Clin Endocrinol Metab; 1992 Sep; 75(3):911-7. PubMed ID: 1517385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily.
    Wilson CA; di Clemente N; Ehrenfels C; Pepinsky RB; Josso N; Vigier B; Cate RL
    Mol Endocrinol; 1993 Feb; 7(2):247-57. PubMed ID: 8469238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of monoclonal antibodies for affinity purification of bovine mullerian inhibiting substance activity.
    Shima H; Donahoe PK; Budzik GP; Kamagata S; Hudson P; Mudgett-Hunter M
    Hybridoma; 1984; 3(3):201-14. PubMed ID: 6548727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a receptor for human müllerian inhibiting substance.
    Catlin EA; Ezzell RM; Donahoe PK; Gustafson ML; Son EV; MacLaughlin DT
    Endocrinology; 1993 Dec; 133(6):3007-13. PubMed ID: 8243329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioassay, purification, cloning, and expression of müllerian inhibiting substance.
    MacLaughlin DT; Epstein J; Donahoe PK
    Methods Enzymol; 1991; 198():358-69. PubMed ID: 1857229
    [No Abstract]   [Full Text] [Related]  

  • 12. [Purification of bovine antimullerian hormone using a monoclonal antibody].
    Josso N; Picard JY; Vigier B
    C R Seances Acad Sci III; 1981 Nov; 293(8):447-50. PubMed ID: 6797694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
    Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
    Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Müllerian-inhibiting substance: an update.
    Donahoe PK; Budzik GP; Trelstad R; Mudgett-Hunter M; Fuller A; Hutson JM; Ikawa H; Hayashi A; MacLaughlin D
    Recent Prog Horm Res; 1982; 38():279-330. PubMed ID: 6896925
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of müllerian inhibiting substance specific binding in human cell lines.
    MacLaughlin DT; Levin RK; Catlin EA; Taylor LA; Preffer FI; Donahoe PK
    Horm Metab Res; 1992 Dec; 24(12):570-5. PubMed ID: 1478615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A possible purification of mullerian inhibiting substance and a model for its mechanism of action.
    Budzik GP; Donahoe PK; Hutson JM
    Prog Clin Biol Res; 1985; 171():207-23. PubMed ID: 2984697
    [No Abstract]   [Full Text] [Related]  

  • 17. Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.
    Kurian MS; de la Cuesta RS; Waneck GL; MacLaughlin DT; Manganaro TF; Donahoe PK
    Clin Cancer Res; 1995 Mar; 1(3):343-9. PubMed ID: 9815990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-idiotypic antibodies to a monoclonal antibody raised against anti-müllerian hormone exhibit anti-müllerian biological activity.
    Lefèvre G; Tran D; Hoebeke J; Josso N
    Mol Cell Endocrinol; 1989 Mar; 62(1):125-33. PubMed ID: 2787251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody to Mullerian inhibiting substance.
    Mudgett-Hunter M; Budzik GP; Sullivan M; Donahoe PK
    J Immunol; 1982 Mar; 128(3):1327-33. PubMed ID: 6895760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line.
    Fuller AF; Guy S; Budzik GP; Donahoe PK
    J Clin Endocrinol Metab; 1982 May; 54(5):1051-5. PubMed ID: 6895900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.